“…Currently, the diagnosis generally is made after the onset of neurological manifestations and heralds a rapidly-fatal course for most patients. Immunocytochemistry techniques, immunophenotyping and biochemical or immunological markers can help in this diagnosis [56,57,66,[71][72][73][74][75][76][77][78]. The analysis of CSF biochemical and cellular characteristics, although not specific for the diagnosis of malignant involvement of the CNS, is important and can help with the diagnosis of CNS neoplasms, when associated with other clinical or biomarker characteristics.…”